Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Perimenopause, Women Health
Interventions: Shatavari (Asparagus racemosus) Root Extract, Placebo Capsule; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 40 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adult Attention Deficit Hyperactivity Disorder
Interventions: OPC-64005, Atomoxetine, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more

Conditions: PMS, Menstrual Cramp, Mood Change
Interventions: PMS Capsule, Capsule Placebo, PMS Gummy, Gummy Placebo; Dietary Supplement
Lead sponsor: Semaine Health; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 176 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Polycythemia Vera
Interventions: Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Newark, Delaware • Eugene, Oregon • Charlottesville, Virginia

Conditions: Asthma
Interventions: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Huntington Beach, California • Newport Beach, California + 19 more

Conditions: Kidney Transplantation, Graft Rejection
Interventions: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Depression
Interventions: Venlafaxine XR, Placebo, JNJ26489112; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Arcadia, California • Escondido, California • San Diego, California + 11 more

Conditions: Type 2 Diabetes
Interventions: Mitoglitazone, Pioglitazone, Placebo; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more

Conditions: Avian Influenza, Bird Flu
Interventions: ND1.1, Placebo control; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Muscle Atrophy, Hypodynamia
Interventions: HPP593, Placebo; Drug
Lead sponsor: High Point Pharmaceuticals, LLC.; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Adults
Interventions: Naltrexone and 2-butanol, 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form); Drug
Lead sponsor: Xhale Assurance; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: PF-03654746, Placebo capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more

Conditions: Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
Interventions: Varenicline, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Perioperative Pain
Interventions: Ibuprofen 600 mg, OxyCODONE 5 Mg Oral Capsule; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: HIV Infections, Substance Use Disorders
Interventions: PrEPsteps, Digital pill, Truvada; Behavioral · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boylston, Massachusetts

Conditions: Autism Spectrum Disorder
Interventions: Fluconazole; Drug
Lead sponsor: The Center for Autism and Related Disorders; Other
Eligibility: 3 Years to 10 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Tarzana, California • Melbourne, Florida • Austin, Texas

Conditions: Parkinson Disease, Parkinsons Disease With Dementia
Interventions: Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Binge Eating Disorder
Interventions: RDC-0313 (ALKS 33), Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Tucson, Arizona • Minneapolis, Minnesota • Manlius, New York + 3 more

Conditions: Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Interventions: Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane; Drug · Procedure
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Heart Failure
Interventions: Potassium Nitrate (KNO3), Potassium Chloride (KCl); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Evanston, Illinois • Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Lower Urinary Track Symptoms
Interventions: Silodosin 8 mg, Placebo; Drug
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide Inhalation Powder; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more

Conditions: Vasectomy, NSAIDs, Post-operative Care
Interventions: Acetaminophen, ibuprofen, oxycodone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Search by objective public record fields.

Shatavari Root Extract for Perimenopausal Symptoms

The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder

A Randomized Placebo-Controlled Study to Evaluate the Effects of a Gummy and Capsule Supplement on Symptoms of Premenstrual Syndrome

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Safety Study of an Oral Vaccine to Prevent Avian Influenza

Safety Study of HPP593 in Subjects During and After Limb Immobilization

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

Pain Control Without Opioids

Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)

Study of Fluconazole in Children With Autism Spectrum Disorder

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Post-Vasectomy Pain Study